SEC Filing Summary
Entity clarification: The supplied 10-Q is for Chavant Capital Acquisition Corp., a SPAC proposing to combine with Mobix Labs, Inc.; it is not Mobix Labs’ operating-company 10-Q. The reporting period ended September 30, 2023. The filing describes Chavant as a shell company that had not commenced operations or generated operating revenue.
Financial results and position
| Metric | Three months ended September 30, 2023 | Nine months ended September 30, 2023 |
|---|---|---|
| Operating expenses | $239,376 | $1,010,314 |
| Net income (loss) | $(5,876) | $(576,029) |
| Trust-account interest and dividends | $88,700 | $313,506 |
| Change in warrant liability | $57,120 gain | $256,020 gain |
| Change in PIPE derivative liability | $87,680 gain | $(135,241) loss |
- At September 30, 2023, assets were $8.69 million, including $8.68 million in the trust account and only $7,525 cash outside the trust. Current liabilities were $2.25 million; total liabilities were $3.53 million. Working capital deficiency was $2.23 million.
- Trust-account funds represented redemption value for 778,912 shares, approximately $11.01 per share. Another 2.0 million founder shares were outstanding. Shareholders’ deficit was $3.41 million.
- Cash used in operating activities was $343,459 for the nine months. Investing activities provided $1.33 million and financing activities used $1.16 million; ending cash was $7,525.
- No operating revenue, operating margin, or business-level cash flow is reported; Chavant had no operating business. The filing reports no long-term debt or lease obligations, but sponsor working-capital loans totaled $1.35 million at quarter-end. A separate sponsor note bears 10% annual interest.
Changes versus prior comparable periods
- Q3 net loss narrowed to $5,876 from $63,074 in Q3 2022. Nine-month results shifted to a $576,029 loss from $576,070 net income in 2022, largely reflecting lower warrant-liability fair-value gains and a loss on the PIPE derivative liability.
- Operating expenses fell to $1.01 million from $1.10 million for the nine-month comparison. Trust-account assets declined from $9.84 million at December 31, 2022, primarily following redemptions, despite extension deposits and accrued trust income.
- Public-share redemptions during 2023 totaled 174,121 shares and $1.85 million. The balance of shares subject to possible redemption fell from 953,033 at year-end 2022 to 778,912.
Transaction, outlook, and principal risks
- Chavant’s proposed Mobix Labs transaction included a $30 million PIPE for 3 million shares at $10 per share, subject to closing conditions. The agreement’s outside date had been extended to November 22, 2023. The filing does not establish that the transaction closed.
- Chavant’s business-combination deadline was January 22, 2024. If it failed to complete a combination by then, it would be required to wind up and redeem public shares; warrants could expire worthless. Closing conditions included shareholder approval, regulatory clearance, and at least $5,000,001 of net tangible assets after redemptions and the PIPE.
- Management said the $7,525 of outside-trust cash was insufficient to fund operations for 12 months absent a business combination. The filing states this raises substantial doubt about Chavant’s ability to continue as a going concern; sponsor funding and a successful transaction were management’s plans, with no assurance of success.
- Nasdaq had cited failure to meet the $35 million minimum market value of listed securities and the 300-public-holder requirement. Chavant requested a hearing and presented a compliance plan on November 9, 2023; a delisting determination remained uncertain. Delisting could reduce liquidity and access to financing.
- Disclosure controls were assessed as ineffective. Unremediated material weaknesses involved staffing and accounting expertise, earnings-per-share and cash-flow classification, complex PIPE accounting, and review of third-party valuations.
- Fair-value changes in warrant and PIPE derivative liabilities materially affected reported results. The PIPE make-whole liability was a Level 3 estimate using a Monte Carlo model and significant unobservable assumptions.
Investor verification checklist
- Confirm the correct issuer and obtain Mobix Labs’ own operating-company filings before assessing its revenue, profitability, cash flow, or debt.
- Check subsequent filings for the transaction’s closing or termination, satisfaction of closing conditions, and status of the $30 million PIPE.
- Verify Nasdaq’s final decision, continued-listing status, and any compliance extension.
- Review subsequent sponsor borrowing, repayment terms, and available cash, given the going-concern warning and minimal outside-trust liquidity.
- Assess redemption levels, remaining trust funds, and the effect of the removed net-tangible-asset redemption limitation on closing feasibility.
- Track remediation of the disclosed internal-control material weaknesses and changes in derivative-liability valuations.